S Janssen1, C Glanzmann, G Huber, G Studer. 1. Department of Radiation Oncology, University Hospital Zurich, Rämistr. 1000, 8091, Zurich, Switzerland.
Abstract
PURPOSE: The goal of the present study was to evaluate the outcome of risk-adapted planning treatment volumes (PTVs) in patients with cervical lymph node metastases of unknown primary cancer (UPC) treated with intensity-modulated radiotherapy (IMRT). PATIENTS AND MATERIAL: Between January 2006 and November 2012, 28 patients with cervical lymph node metastases of UPC were treated in our institution with IMRT either postoperatively (n = 20) or as definitive treatment (n = 8). Nodal involvement distributed as follows: N1 (n = 2), N2a (8), N2b (10), N2c (4), and N3 (4). Systemic therapy with cisplatin or cetuximab was added concomitantly in 20 of 28 patients (71 %). Radiotherapy using simultaneously integrated boost (SIB-IMRT) was carried out with 2.0 or 2.11 Gy single doses up to 66/70 Gy. RESULTS: Mean/median follow-up was 31.6/30.5 months (range 3-78 months). In all, 15 of 28 patients were treated with unilateral SIB-IMRT (54 %). An elective PTV to the contralateral oropharynx and contralateral level II-III lymph nodes was carried out in 8 patients with PET-CT suspected but not histologically proven involvement, recurrences or former tumor of the oropharynx. More extended treatment fields were reserved for patients with N2c or bilaterally N3 status (n = 5). The 3-year overall survival, mucosal control, neck control and distant metastasis-free survival rates were 76, 100, 93, and 88 %, respectively. No patient suffered from a locoregional recurrence. Two patients treated with radiotherapy alone had persistent nodal disease. No grade II or higher late sequel has been observed. CONCLUSION: Our single center approach to treat patients with cervical lymph node metastases of UPC with individualized, risk-adapted SIB-IMRT resulted in high locoregional tumor control and was well tolerated.
PURPOSE: The goal of the present study was to evaluate the outcome of risk-adapted planning treatment volumes (PTVs) in patients with cervical lymph node metastases of unknown primary cancer (UPC) treated with intensity-modulated radiotherapy (IMRT). PATIENTS AND MATERIAL: Between January 2006 and November 2012, 28 patients with cervical lymph node metastases of UPC were treated in our institution with IMRT either postoperatively (n = 20) or as definitive treatment (n = 8). Nodal involvement distributed as follows: N1 (n = 2), N2a (8), N2b (10), N2c (4), and N3 (4). Systemic therapy with cisplatin or cetuximab was added concomitantly in 20 of 28 patients (71 %). Radiotherapy using simultaneously integrated boost (SIB-IMRT) was carried out with 2.0 or 2.11 Gy single doses up to 66/70 Gy. RESULTS: Mean/median follow-up was 31.6/30.5 months (range 3-78 months). In all, 15 of 28 patients were treated with unilateral SIB-IMRT (54 %). An elective PTV to the contralateral oropharynx and contralateral level II-III lymph nodes was carried out in 8 patients with PET-CT suspected but not histologically proven involvement, recurrences or former tumor of the oropharynx. More extended treatment fields were reserved for patients with N2c or bilaterally N3 status (n = 5). The 3-year overall survival, mucosal control, neck control and distant metastasis-free survival rates were 76, 100, 93, and 88 %, respectively. No patient suffered from a locoregional recurrence. Two patients treated with radiotherapy alone had persistent nodal disease. No grade II or higher late sequel has been observed. CONCLUSION: Our single center approach to treat patients with cervical lymph node metastases of UPC with individualized, risk-adapted SIB-IMRT resulted in high locoregional tumor control and was well tolerated.
Authors: Hugo Villeneuve; Philippe Després; Bernard Fortin; Edith Filion; David Donath; Denis Soulières; Louis Guertin; Tarek Ayad; Apostolos Christopoulos; Phuc Felix Nguyen-Tan Journal: Int J Radiat Oncol Biol Phys Date: 2011-04-15 Impact factor: 7.038
Authors: Primož Strojan; Alfio Ferlito; Jesus E Medina; Julia A Woolgar; Alessandra Rinaldo; K Thomas Robbins; Johannes J Fagan; William M Mendenhall; Vinidh Paleri; Carl E Silver; Kerry D Olsen; June Corry; Carlos Suárez; Juan P Rodrigo; Johannes A Langendijk; Kenneth O Devaney; Luiz P Kowalski; Dana M Hartl; Missak Haigentz; Jochen A Werner; Phillip K Pellitteri; Remco de Bree; Gregory T Wolf; Robert P Takes; Eric M Genden; Michael L Hinni; Vanni Mondin; Ashok R Shaha; Leon Barnes Journal: Head Neck Date: 2011-10-27 Impact factor: 3.147
Authors: Allen M Chen; Bao-Qing Li; D Gregory Farwell; Joseph Marsano; Srinivasan Vijayakumar; James A Purdy Journal: Int J Radiat Oncol Biol Phys Date: 2010-04-24 Impact factor: 7.038
Authors: Debora Beldì; Barbara A Jereczek-Fossa; Alberto D'Onofrio; Giuseppina Gambaro; Maria Rosaria Fiore; Francesco Pia; Fausto Chiesa; Roberto Orecchia; Marco Krengli Journal: Int J Radiat Oncol Biol Phys Date: 2007-08-22 Impact factor: 7.038
Authors: Gabriela Studer; Katrin Furrer; Bernard J Davis; Sandro S Stoeckli; Roger A Zwahlen; Urs M Luetolf; Christoph Glanzmann Journal: Radiat Oncol Date: 2006-10-19 Impact factor: 3.481